CSL787

CSL787 is a nebulized human plasma-derived polyvalent immunoglobulin G (IgG) product administered via inhalation of an aerosol produced using a nebulizer. It contains approximately 250 mmol/L of L-proline as a stabilizer and trace amounts of sodium. The drug is designed for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Non-Cystic Fibrosis Bronchiectasis (NCFB). It aims to increase immune defense in patients with recurrent respiratory infections by targeting antibodies directly into the lungs, potentially decreasing infection frequency and disease exacerbations.

Other names

Nebulised immunoglobulinNebulized immunoglobulin